GlassScriptPhysician profile
Corrine G Miller
NPI 1669225215
$2,447.58
in general payments reported to CMS, 2019-2025
23 companies · $1,892 in 2025
The $1,892 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $555 · 2025: $1,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,348 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,347.63 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $621.31 | 2024-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $245.99 | 2024-2025 | Nucala, Trelegy Ellipta |
| United Therapeutics Corporation | $229.48 | 2024-2025 | Tyvaso, Orenitram, Tyvaso |
| Regeneron Healthcare Solutions, INC. | $214.67 | 2024-2025 | Dupixent |
| Genzyme Corporation | $131.78 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $128.17 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $107.99 | 2024-2025 | Glassia |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Merck Sharp & Dohme LLC | $78.51 | 2024-2025 | Winrevair, Keytruda |
| Paratek Pharmaceuticals, INC. | $69.36 | 2024-2025 | Nuzyra |
| Avadel Cns Pharmaceuticals, LLC | $67.66 | 2024-2025 | Lumryz |
| Mylan Specialty L.P. | $59.99 | 2024 | Yupelri |
| Verona Pharma, INC. | $58.48 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $55.17 | 2025 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $48.95 | 2025 | Uptravi, Opsumit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fisher & Paykel Healthcare INC | $46.28 | 2025 | Fisher & Paykel Healthcare |
| Lilly USA, LLC | $39.67 | 2025 | Zepbound |
| Harmony Biosciences LLC | $38.02 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.96 | 2025 | Ofev |
| Grifols USA, LLC | $23.08 | 2025 | Prolastin-C Liquid |
| Csl Behring | $22.84 | 2025 | Hizentra |
| Pulmonx Corporation | $16.51 | 2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Chiesi USA, INC. | $15.76 | 2024 | Cleviprex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corrine Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.